IDEXX Laboratories, Inc. (IDXX) Chairman Sells $3,905,440.00 in Stock

IDEXX Laboratories, Inc. (NASDAQ:IDXX) Chairman Jonathan W. Ayers sold 22,000 shares of the business’s stock in a transaction that occurred on Thursday, February 8th. The shares were sold at an average price of $177.52, for a total value of $3,905,440.00. Following the completion of the sale, the chairman now owns 1,077,112 shares of the company’s stock, valued at $191,208,922.24. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

Shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) opened at $172.95 on Friday. The company has a market capitalization of $14,764.38, a P/E ratio of 53.57, a PEG ratio of 2.08 and a beta of 0.58. IDEXX Laboratories, Inc. has a 12-month low of $140.63 and a 12-month high of $198.73. The company has a debt-to-equity ratio of -11.26, a current ratio of 0.97 and a quick ratio of 0.80.

IDEXX Laboratories (NASDAQ:IDXX) last posted its quarterly earnings data on Thursday, February 1st. The company reported $0.77 EPS for the quarter, beating the Zacks’ consensus estimate of $0.73 by $0.04. IDEXX Laboratories had a negative return on equity of 432.19% and a net margin of 13.36%. The business had revenue of $506.00 million during the quarter, compared to analysts’ expectations of $490.51 million. During the same period in the previous year, the business earned $0.58 earnings per share. The business’s revenue was up 14.2% compared to the same quarter last year. sell-side analysts anticipate that IDEXX Laboratories, Inc. will post 4.09 EPS for the current fiscal year.

Institutional investors and hedge funds have recently modified their holdings of the stock. D.A. Davidson & CO. increased its position in shares of IDEXX Laboratories by 160.4% during the second quarter. D.A. Davidson & CO. now owns 625 shares of the company’s stock worth $100,000 after purchasing an additional 385 shares in the last quarter. BB&T Investment Services Inc. purchased a new stake in shares of IDEXX Laboratories during the second quarter worth approximately $104,000. Zions Bancorporation purchased a new stake in shares of IDEXX Laboratories during the third quarter worth approximately $162,000. Benjamin F. Edwards & Company Inc. increased its position in shares of IDEXX Laboratories by 1,000.0% during the fourth quarter. Benjamin F. Edwards & Company Inc. now owns 1,100 shares of the company’s stock worth $172,000 after purchasing an additional 1,000 shares in the last quarter. Finally, SignalPoint Asset Management LLC purchased a new stake in shares of IDEXX Laboratories during the fourth quarter worth approximately $200,000. Hedge funds and other institutional investors own 86.72% of the company’s stock.

IDXX has been the subject of a number of recent analyst reports. Zacks Investment Research upgraded IDEXX Laboratories from a “hold” rating to a “buy” rating and set a $184.00 price objective for the company in a research report on Tuesday, October 24th. Stifel Nicolaus restated a “buy” rating and issued a $185.00 price objective on shares of IDEXX Laboratories in a research report on Tuesday, October 24th. BidaskClub cut IDEXX Laboratories from a “hold” rating to a “sell” rating in a research report on Saturday, December 16th. Piper Jaffray Companies initiated coverage on IDEXX Laboratories in a research report on Tuesday, January 16th. They issued an “overweight” rating and a $200.00 price objective for the company. Finally, Aegis restated a “sell” rating on shares of IDEXX Laboratories in a research report on Friday, December 8th. One research analyst has rated the stock with a sell rating, six have given a buy rating and one has assigned a strong buy rating to the company. The company currently has an average rating of “Buy” and a consensus price target of $194.00.

WARNING: This article was first posted by Community Financial News and is the property of of Community Financial News. If you are viewing this article on another website, it was illegally copied and reposted in violation of U.S. & international copyright and trademark laws. The correct version of this article can be accessed at https://www.com-unik.info/2018/02/10/idexx-laboratories-inc-idxx-chairman-sells-3905440-00-in-stock.html.

About IDEXX Laboratories

IDEXX Laboratories, Inc develops, manufactures and distributes products and provides services for the companion animal veterinary, livestock and poultry, dairy and water testing markets. The Company also sells a line of portable electrolytes and blood gas analyzers for the human point-of-care medical diagnostics market.

Insider Buying and Selling by Quarter for IDEXX Laboratories (NASDAQ:IDXX)

Receive News & Ratings for IDEXX Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit